The Duchenne muscular dystrophy (DMD) market is projected to grow from $2.3 billion in 2023 to $5.2 billion in 2033 across seven major markets, driven by recent approvals of novel therapies, says ...

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

Pratteln, Switzerland Friday, February 14, 2025, 15:00 Hrs [IST] ...

The Swiss biopharma company said the deal with the German National Association of Statutory Health Insurance Funds (GKV-SV) ...

Santhera Pharmaceuticals, a Swiss specialty pharma focused on rare diseases, has announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...

Catherine Isted, an experienced healthcare CFO with over 25 years in life sciences, appointed as CFO effective February 24, 2025Current CFO ...

For the third quarter, its net income was $43.9 million, or $0.35 per diluted share, which is a substantial turnaround from ...

Agreement drives continued patient access to four important therapies in Japan and Korea Strengthens Essential Pharma and Clinigen's combined market presence in the JAPAC region Egham, UK - 6th ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...

Baird initiated coverage on Catalyst Pharmaceutical Partners (NASDAQ:CPRX) with an Outperform rating and set a price target of $28.00. The firm highlighted Catalyst Pharma's successful ...